Volitionrx Ltd SEC filings VNRX
Volitionrx Ltd has 1,004 filings in SEC EDGAR's recent list, going back to Aug 27, 2013. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (material agreement, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 9, 2026 | — |
| EFFECT | Filing | Jul 17, 2026 | — |
| EFFECT | Filing | Feb 19, 2026 | — |
| CORRESP | Letter to the SEC | Feb 17, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2026 | — |
| D/A | Filing | Jan 28, 2026 | — |
| EFFECT | Filing | Jul 14, 2025 | — |
| CORRESP | Letter to the SEC | Jul 10, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2025 | — |
| D | Filing | May 30, 2025 | — |
| RW WD | Filing | Apr 25, 2025 | — |
| EFFECT | Filing | Apr 18, 2025 | — |
| CORRESP | Letter to the SEC | Apr 16, 2025 | — |
| RW | Filing | Apr 16, 2025 | — |
| EFFECT | Filing | Apr 15, 2025 | — |
| CORRESP | Letter to the SEC | Apr 11, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2025 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2024 | — |
| EFFECT | Filing | Jun 25, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2024 | — |
| D | Filing | Mar 26, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2024 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2023 | — |
| EFFECT | Filing | Nov 8, 2021 | — |
| CORRESP | Letter to the SEC | Nov 4, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2021 | — |
| EFFECT | Filing | Feb 14, 2020 | — |
| CORRESP | Letter to the SEC | Feb 13, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2020 | — |
| CORRESP | Letter to the SEC | Feb 13, 2020 | — |
| EFFECT | Filing | Oct 15, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2018 | — |
| CORRESP | Letter to the SEC | Oct 12, 2018 | — |
| EFFECT | Filing | Sep 28, 2018 | — |
| CORRESP | Letter to the SEC | Sep 26, 2018 | — |
| CORRESP | Letter to the SEC | Sep 26, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2018 | — |
| D | Filing | Aug 27, 2018 | — |
| EFFECT | Filing | Sep 18, 2015 | — |
| CORRESP | Letter to the SEC | Sep 16, 2015 | — |
| UPLOAD | Letter from the SEC | Sep 15, 2015 | — |
| EFFECT | Filing | Jun 26, 2015 | — |
| CORRESP | Letter to the SEC | Jun 24, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 22, 2015 | — |
| EFFECT | Filing | Feb 5, 2015 | — |
| CERTNYS | Auto-generated paper document | Feb 4, 2015 | — |
| 8-A12B | Form 8-a 12(b) | Feb 3, 2015 | — |
| AW | Form aw | Jan 8, 2015 | — |
| D | Filing | Nov 21, 2014 | — |
| D | Filing | Oct 14, 2014 | — |
| D | Filing | Oct 14, 2014 | — |
| D | Filing | Sep 25, 2014 | — |
| EFFECT | Filing | Apr 25, 2014 | — |
| D | Filing | Mar 11, 2014 | — |
| D | Filing | Dec 3, 2013 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VNRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 93314
- Former names
- VOLITIONRX LTD (until Oct 27, 2026); STANDARD CAPITAL CORP (until Sep 29, 2011)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.